Publication | Open Access

Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

Advanced Breast CancerBreast OncologyOncologyMedicineAromatasePharmacotherapyBreast CancerMenopause Hormone TherapyAnti-cancer AgentPharmacologyRadiation OncologyCancer ResearchEndocrine-related CancerPostmenopausal Women